Spots Global Cancer Trial Database for To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC
Official Title: A Multicenter, Open-label, Randomized, Controlled Phase II Study to Evaluate the Efficacy and Safety of Afatinib Versus Irinotecan as a Second-line and Above Treatment for Advanced ALTRK-negative ESCC
Study ID: NCT05818982
Study Description
Brief Summary: This is a phase II study to evaluate the effectiveness and safety of Afininib compared to irinotecan in the 3-gene RNA sequencing (ALTRK) negative advanced esophageal squamous squamous carcinoma.
Detailed Description: Participants were assigned to either group A or group B at 2:1 randomization (block randomization). Group A received afatinib (40 mg orally/day) every 6 weeks; Group B received irinotecan (140-180mg/m2 intravenous) every 2 weeks.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Cancer Hospital, Beijing, China, Beijing, , China
First Hospital of Xiamen University Affiliated Hospital,Xiamen,China, Xiamen, , China
Xinxiang Central Hospital of Henan Province, Xinxiang, China, Xinxiang, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
